Iqbal Umair, Perumpail Brandon J, John Nimy, Sallam Sandy, Shah Neha D, Kwong Waiyee, Cholankeril George, Kim Donghee, Ahmed Aijaz
Department of Medicine, Geisinger Medical Center, Danville, PA 17821, USA.
Drexel University College of Medicine, Philadelphia, PA 19104, USA.
Diseases. 2018 Sep 24;6(4):87. doi: 10.3390/diseases6040087.
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world. NAFLD encompasses a spectrum of histological features, including steatosis, steatohepatitis with balloon degeneration, and hepatic fibrosis leading to cirrhosis. In patients with advanced liver damage, NAFLD is associated with an increased risk of hepatocellular carcinoma. Diabetes mellitus, hypertension, and dyslipidemia are components of metabolic syndrome and are commonly associated with NAFLD. Cardiovascular disease is the leading cause of mortality in patients with NAFLD. Therefore, it is important to pre-emptively identify and proactively treat conditions like hyperlipidemia in an effort to favorably modify the risk factors associated with cardiovascular events in patients with NAFLD. The management of hyperlipidemia has been shown to reduce cardiovascular mortality and improve histological damage/biochemical abnormalities associated with non-alcoholic steatohepatitis (NASH), a subset of NAFLD with advance liver damage. There are no formal guidelines available regarding the use of anti-hyperlipidemic drugs, as prospective data are lacking. The focus of this article is to discuss the utility of lipid-lowering drugs in patients with NAFLD.
非酒精性脂肪性肝病（NAFLD）是西方世界慢性肝病最常见的病因。NAFLD包括一系列组织学特征，包括脂肪变性、伴有气球样变的脂肪性肝炎以及导致肝硬化的肝纤维化。在晚期肝损伤患者中，NAFLD与肝细胞癌风险增加相关。糖尿病、高血压和血脂异常是代谢综合征的组成部分，通常与NAFLD相关。心血管疾病是NAFLD患者死亡的主要原因。因此，预先识别并积极治疗高脂血症等病症，以有利地改变NAFLD患者心血管事件相关的危险因素，这一点很重要。高脂血症的管理已被证明可降低心血管死亡率，并改善与非酒精性脂肪性肝炎（NASH，NAFLD的一个伴有晚期肝损伤的子集）相关的组织学损伤/生化异常。由于缺乏前瞻性数据，目前尚无关于使用抗高脂血症药物的正式指南。本文的重点是讨论降脂药物在NAFLD患者中的效用。
